Antibiotic-Resistant Infections Cost the U.S. Healthcare System in Excess of $20 Billio...(n the year 2000 and apply the same selec...),Health

Date:10/19/2009

n the year 2000 and apply the same selection criteria used in that study nationwide, there would have been nearly 900,000 cases of ARIs in the year 2000." By applying the range of additional costs seen in the Cook County (Stroger) Hospital study of $18,588 to $29,069 to this enormous number of ARIs, we could conceivably avoid $16.6 billion on the low end and up to $26 billion in additional healthcare costs stemming from the treatment of these preventable infections: "Even a 20% reduction in these infections would save between $3.2 and $5.2 billion a year and between 5.7 and 11.3 million additional days in the hospital. Clearly, any discussion of healthcare reform must look at the cost of current clinical practice and the savings we could realize if we used antibiotics more prudently," noted Dr. Roberts. "Imagine if these hospital beds and healthcare resources were used instead for preventive care or for under-served patients," she added.

"Assuming 900,000 ARI cases in the year 2000, based on the conservative selection criteria used in our study, the total societal costs of ARIs to U.S. households in the year 2000 was approximately $35 billion," Dr. Roberts added. "This includes lost wages from extended hospital stays and from premature deaths."(1)

"Keep in mind these data were collected in 2000, and the rate of notifications of antibiotic resistant cases has more than doubled since then, so these figures should be viewed as very conservative; further work is ongoing to estimate the current burden at state and national levels," said Prof. Susan Foster, a co-author and health economist at APUA.

"Another mitigating factor that may also cause us to underestimate the true burden is the excellent clinical practice where the study actually occurred," said Dr. Levy. "To its credit, Cook County (Stroger) Hospital happens to have an enviably low rate of healthcare associated infections, including ARIs."

A study suggested by the
'/>"/>

SOURCE bioMerieux Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal
2. Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections
3. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
4. Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
5. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
6. NovaBay Launches Clinical Study for Non-Antibiotic Treatment of Impetigo, One of the Most Common Skin Infections
7. University of Michigan Study Shows SEQUENOMs MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
8. Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections
9. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
10. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
11. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections